NGVTIngevity Corp
Chemicals & Allied Products
- Revenue
- $1.2B
- 2.7% YoY
- Operating margin
- 35.9%
- 1.0% YoY
- EBITDA
- $525M
- 1.7% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- 2.3×
- $1.2B net debt
- AI in 10-K
- —
Red flags 0 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCClear2% of revenueOver 10% of revenue
- Payouts exceed cash flowClear17% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear0% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $1.4B | $1.7B | $1.2B | $1.2B | $1.2B | 2.7% |
| Operating income | $422M | $453M | $423M | $426M | $419M | 1.7% |
| Net income | $118M | $212M | −$5M | −$430M | −$167M | 61% |
| Operating cash flow | $293M | $313M | $205M | $129M | $331M | 158% |
| Capex | $104M | $143M | $110M | $78M | $58M | 26% |
| Stock-based comp | $12M | $16M | $11M | $12M | $18M | 54% |
| Buybacks | $109M | $145M | $92M | $0 | $56M |
Deal filings
None.
13D filers
None on file.
Insider trading
No open-market trades in the last 12 months.
Pay vs performance
No pay-versus-performance disclosure yet.